Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea
Key facts
- Who runs it
- CHOSEOK YOON
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 100 people, planned
- Started
- 15 Jun 2025
- Expected to end
- 1 Feb 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Piperacillin/Tazobactam
- Piperacillin/tazobactam + Levofloxacin
- Record updated
- 18 May 2025
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Other criteria
- Inclusion Criteria:; Adult patients aged 19 years or older who visited the emergency department and were hospitalized; Findings consistent with pneumonia diagnosis, meeting all of the following criteria:; Radiologic evidence of pulmonary infiltration on chest X-ray or chest CT; At least two or more of the following clinical signs:; Body temperature ≥38°C or <36°C ii) White blood cell count ≥11,000/µL or <4,000/µL iii) Presence of purulent sputum or bronchial secretions; Within 24 hours of admission, the patient meets one major criterion or three minor criteria according to ATS/IDSA classification:; Major criteria:; Invasive mechanical ventilation ii) Use of vasopressors (vasopressor-dependent septic shock); Minor criteria:; Respiratory rate ≥30 breaths/min ii) PaO2/FiO2 ≤ 250 iii) Multilobar infiltrates iv) Confusion or disorientation v) BUN ≥20 mg/dL vi) WBC <4,000/mm³ vii) Platelet count <100,000/mm³ viii) Hypothermia (temperature <36°C) ix) Hypotension requiring aggressive fluid resuscitation
- Exclusion Criteria:; Transferred from another hospital after >48 hours of hospitalization; Died within 72 hours of hospital admission; Transferred to another hospital within 14 days of admission; Pneumonia occurring after >48 hours of mechanical ventilation, including home ventilators; Detection of influenza or SARS-CoV-2 virus within 7 days of hospitalization; Identified non-pneumonia infection requiring antibiotics within 72 hours of admission; Detection of piperacillin/tazobactam-resistant Enterobacterales, Pseudomonas spp., or Acinetobacter spp. in respiratory or blood cultures within the past 90 days; Antibiotic-related adverse events observed within 72 hours of assigned treatment, requiring discontinuation or change of antibiotics
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to provide high-level evidence for appropriate empirical antibiotic use tailored to the clinical reality in Korea by conducting a randomized controlled trial comparing monotherapy with piperacillin/tazobactam and combination therapy with piperacillin/tazobactam plus a fluoroquinolone in patients with severe community-acquired pneumonia.
The 2 groups in the trial
- Piperacillin/Tazobactam MonotherapyTreatment being tested
Patients receive empirical treatment with piperacillin/tazobactam alone for severe community-acquired pneumonia. The antibiotic is administered according to standard dosing guidelines for hospitalized patients.
Treatment: Piperacillin/Tazobactam
- Piperacillin/Tazobactam Plus Levofloxacin Combination TherapyExisting treatment, for comparison
Patients receive empirical combination treatment with piperacillin/tazobactam and levofloxacin for severe community-acquired pneumonia. Both antibiotics are administered concurrently according to institutional protocols for combination therapy.
Treatment: Piperacillin/tazobactam + Levofloxacin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Verification of Anti-pseudomonal Antibiotic Combination Therapy in Severe Community-acquired Pneumonia in South Korea: A Randomized-controlled Study
- Record updated
- 18 May 2025